Friday’s closing price of €80.20 left BioNTech down 1.41% on the day and 4.86% lower on the week, but the stock has managed a 7.36% gain over the past month. That seesaw pattern captures the tension investors are wrestling with: a company that still commands €16.8 billion in cash and equivalents but is burning through that cushion at a rate of more than half a billion euros per quarter as it pivots away from the Covid-19 franchise that made it a household name.
The first-quarter numbers illustrate the cost of that transition. Revenue slumped to €118.1 million from €182.8 million a year earlier, driven by fading vaccine sales, while the net loss widened to €531.9 million. Research spending alone hit €557 million in the period, most of it flowing into immuno-oncology and antibody-drug conjugates. Despite the red ink, management is sticking with its full-year revenue forecast of €2.0 billion to €2.3 billion and has authorised a share buyback programme of up to $1 billion over twelve months.
Reshaping the Manufacturing Footprint
The expense side of the equation is getting a structural overhaul. BioNTech will close its sites in Idar-Oberstein, Marburg and Singapore, along with the former CureVac facilities it inherited. Up to 1,860 jobs are affected, with Idar-Oberstein, Marburg and Tübingen to be wound down by the end of 2027 and the Singapore site shuttered in the first quarter of that year. Once all measures are fully implemented, the company expects annual savings of roughly €500 million from 2029.
That restructuring coincides with a more disruptive change at the top. Founders Ugur Sahin and Özlem Türeci plan to step back from their current roles by the end of 2026 to pursue next-generation mRNA innovation in a new venture. The timing puts a leadership vacuum alongside the most intense period of clinical development in the company’s history.
15 Phase-3 Trials and a First FDA Filing in Sight
BioNTech is running more than 25 Phase-2 or Phase-3 studies in oncology today and intends to have 15 Phase-3 programmes active simultaneously by the end of 2026. Seven major data readouts from late-stage trials are scheduled for this year, five of which are considered potentially registration-enabling. The most closely watched candidate is pumitamig, a bispecific immunomodulator that combines PD-L1 checkpoint inhibition with VEGF-A neutralisation and is being developed with Bristol Myers Squibb. Interim data are already in hand, with further analyses due over the coming months.
Should investors sell immediately? Or is it worth buying BioNTech?
Another near-term milestone sits outside the internal pipeline. BioNTech is preparing to file with the US Food and Drug Administration for trastuzumab pamirtecan, an antibody-drug conjugate licensed from Duality Biologics that targets previously treated HER2-positive uterine cancer. The management sees that submission as a test case for building the commercial infrastructure that would eventually support products such as pumitamig. Still, the company has cautioned that meaningful revenue from oncology drugs is unlikely before 2027 at the earliest.
The August Report Holds the Next Clues
No BioNTech-specific catalysts are scheduled for the current week, but the second-quarter earnings release on 4 August will be the next critical checkpoint. In the first quarter the company posted a loss of $2.28 per share, which beat the consensus estimate of a $2.52 loss, and investors will be watching for any updates on the Phase-3 timeline and the FDA submission.
In the meantime, broader market forces are also in play. The US consumer price index is due on Tuesday, producer prices on Wednesday, and Federal Reserve Chairman Kevin Warsh is set to deliver his semi-annual monetary policy testimony on both days. Those events could sway sentiment for the entire biotech sector, where Goldman Sachs Research recently lifted its 2030 revenue forecast for obesity drugs to $114 billion and the hunt for new assets by large pharma continues to fuel dealmaking.
Technicals Stay Neutral Ahead of the Catalysts
The stock’s chart offers little directional conviction. At €80.20, BioNTech sits just above its 50-day moving average of €79.38 but remains 5.79% below the 200-day average of €85.13. It is 24.20% off the 52-week high of €105.80 touched on 22 January and 17.34% above the year low of €68.35 from 10 March. The relative strength index at 48.5 signals neither overbought nor oversold territory, while the 30-day annualised volatility of 28.71% reflects the uncertainty that surrounds a company spending heavily to reinvent itself before its founders walk out the door.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from July 12 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 12.
BioNTech: Buy or sell? Read more here...
